Compare · CI vs EXAS
CI vs EXAS
Side-by-side comparison of The Cigna Group (CI) and Exact Sciences Corporation (EXAS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CI and EXAS operate in Medical Specialities (Health Care), so they compete in similar markets.
- CI is the larger of the two at $76.58B, about 6.3x EXAS ($12.19B).
- Over the past year, CI is down 7.0% and EXAS is up 92.1% - EXAS leads by 99.1 points.
- CI has hit the wire 4 times in the past 4 weeks while EXAS has been quiet.
- Both have 25 recent analyst ratings on file.
- Company
- The Cigna Group
- Exact Sciences Corporation
- Price
- $289.49+3.10%
- $104.94+1.02%
- Market cap
- $76.58B
- $12.19B
- 1M return
- +2.69%
- +1.60%
- 1Y return
- -7.00%
- +92.13%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- 2001
- News (4w)
- 4
- 0
- Recent ratings
- 25
- 25
The Cigna Group
Cigna Corporation provides insurance and related products and services in the United States. Its Evernorth segment provides a range of coordinated and point solution health services, including pharmacy, benefits management, care, and intelligence solutions to health plans, employers, government organizations, and health care providers. The company's U.S. Medical segment offers commercial products and services, including medical, pharmacy, behavioral health, dental, vision, health advocacy programs, and other products and services for insured and self-insured customers; Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, as well as Medicaid plans; and individual health insurance plans to on and off the public exchanges. Its International Markets segment offers health coverage, hospitalization, dental, critical illness, personal accident, term life, medical cost containment, and variable universal life products, as well as health care benefits to mobile employees of multinational organizations. The company distributes its products and services through insurance brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was founded in 1792 and is headquartered in Bloomfield, Connecticut.
Exact Sciences Corporation
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype MAP, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
Latest CI
- EVP, Global CIO Koka Durga Prasad covered exercise/tax liability with 729 shares, decreasing direct ownership by 10% to 6,552 units (SEC Form 4) (withholding tax)
- SEC Form 4 filed by Director Kurian George
- The Cigna Group downgraded by Barclays with a new price target
- The Cigna Group downgraded by Deutsche Bank with a new price target
- Chairman & CEO Cordani David exercised 212,543 shares at a strike of $170.34 and sold $59,114,186 worth of shares (201,878 units at $292.82) as part of a pre-agreed trading plan, increasing direct ownership by 23% to 57,766 units (SEC Form 4)
- The Cigna Group filed SEC Form 8-K: Regulation FD Disclosure
- The Cigna Group Announces Appearance at the BofA Securities 2026 Health Care Conference
- Kayne Anderson Energy Infrastructure Fund Announces Appointment of Michael J. Hennigan as New Independent Director
- SEC Form 144 filed by The Cigna Group
- SEC Form 10-Q filed by The Cigna Group
Latest EXAS
- SEC Form 15-12G filed by Exact Sciences Corporation
- Amendment: SEC Form SCHEDULE 13G/A filed by Exact Sciences Corporation
- SEC Form POSASR filed by Exact Sciences Corporation
- SEC Form S-8 POS filed by Exact Sciences Corporation
- SEC Form S-8 POS filed by Exact Sciences Corporation
- SEC Form S-8 POS filed by Exact Sciences Corporation
- SEC Form S-8 POS filed by Exact Sciences Corporation
- SEC Form S-8 POS filed by Exact Sciences Corporation
- SEC Form S-8 POS filed by Exact Sciences Corporation
- SEC Form S-8 POS filed by Exact Sciences Corporation